O	0	9	Measuring
O	10	13	the
O	14	20	impact
O	21	23	of
B-intervention	24	33	guideline
I-intervention	33	34	-
I-intervention	34	39	based
I-intervention	40	50	antiemetic
I-intervention	51	58	therapy
O	59	61	on
B-condition	62	68	nausea
I-condition	69	72	and
I-condition	73	81	vomiting
I-condition	82	89	control
O	90	92	in
O	93	99	breast
O	100	106	cancer
O	107	115	patients
O	116	120	with
O	121	129	multiple
O	130	134	risk
O	135	142	factors
O	142	143	.

O	144	147	The
O	148	157	objective
O	158	160	of
O	161	165	this
O	166	177	exploratory
O	178	186	analysis
O	187	190	was
O	191	193	to
O	194	203	determine
O	204	206	if
O	207	217	individual
O	218	225	patient
O	226	230	risk
O	231	238	factors
O	239	244	could
O	245	247	be
O	248	252	used
O	253	255	to
O	256	264	optimize
O	265	277	chemotherapy
O	277	278	-
O	278	285	induced
O	286	292	nausea
O	293	296	and
O	297	305	vomiting
O	306	307	(
O	307	311	CINV
O	311	312	)
O	312	313	.

O	314	321	Through
O	322	331	validated
O	332	336	risk
O	337	347	prediction
O	348	354	models
O	355	360	which
O	361	369	quantify
O	370	377	patient
O	378	382	risk
O	383	390	factors
O	390	391	,
B-total-participants	392	395	152
B-eligibility	396	404	patients
I-eligibility	405	409	with
I-eligibility	410	415	early
I-eligibility	415	416	-
I-eligibility	416	421	stage
I-eligibility	422	428	breast
I-eligibility	429	435	cancer
I-eligibility	436	445	scheduled
I-eligibility	446	448	to
I-eligibility	449	457	received
I-eligibility	458	466	adjuvant
I-eligibility	467	480	anthracycline
I-eligibility	480	481	-
I-eligibility	481	486	based
I-eligibility	487	499	chemotherapy
O	500	504	were
O	505	516	categorized
O	517	519	as
O	520	525	being
O	526	528	at
O	529	532	low
O	533	534	(
O	534	539	level
O	540	541	0
O	541	542	)
O	543	545	or
O	546	550	high
O	550	551	-
O	551	555	risk
O	556	557	(
O	557	562	level
O	563	564	1
O	564	565	)
O	566	569	for
O	570	574	CINV
O	574	575	.

O	576	581	Prior
O	582	584	to
O	585	588	the
O	589	594	first
O	595	600	cycle
O	601	603	of
O	604	616	chemotherapy
O	616	617	,
O	618	621	low
O	621	622	-
O	622	626	risk
O	627	635	patients
O	636	644	received
O	645	656	ondansetron
O	657	660	and
O	661	674	dexamethasone
O	674	675	,
O	676	681	while
O	682	686	high
O	686	687	-
O	687	691	risk
O	692	697	level
O	698	699	1
O	700	708	patients
O	709	713	also
O	714	722	received
O	723	733	aprepitant
O	733	734	.

O	735	738	For
O	739	749	subsequent
O	750	756	cycles
O	756	757	,
O	758	766	patients
O	767	770	who
O	771	782	experienced
O	783	787	CINV
O	788	791	had
O	792	797	their
O	798	809	antiemetics
O	810	817	changed
O	818	820	in
O	821	822	a
O	823	831	stepwise
O	832	838	manner
O	839	841	to
O	842	847	level
O	848	849	2
O	850	851	(
O	851	859	extended
O	859	860	-
O	860	868	duration
O	869	882	dexamethasone
O	882	883	)
O	884	886	or
O	887	892	level
O	893	894	3
O	895	896	(
O	896	904	extended
O	904	905	-
O	905	913	duration
O	914	927	dexamethasone
O	928	931	and
O	932	935	low
O	935	936	-
O	936	940	dose
O	941	951	olanzapine
O	951	952	)
O	952	953	.

O	954	957	The
O	958	963	study
O	964	972	enrolled
B-total-participants	973	976	152
O	977	985	patients
O	986	989	who
O	990	998	received
O	999	1002	484
O	1003	1009	cycles
O	1010	1012	of
O	1013	1025	chemotherapy
O	1025	1026	.

O	1027	1032	Forty
O	1033	1040	patient
O	1041	1047	cycles
O	1048	1052	were
O	1053	1063	classified
O	1064	1066	as
O	1067	1070	low
O	1071	1075	risk
O	1076	1077	(
O	1077	1082	level
O	1083	1084	0
O	1084	1085	)
O	1086	1094	compared
O	1095	1097	to
O	1098	1101	201
O	1101	1102	,
O	1103	1106	162
O	1107	1110	and
O	1111	1113	81
O	1114	1118	that
O	1119	1123	were
O	1124	1134	classified
O	1135	1137	as
O	1138	1142	high
O	1142	1143	-
O	1143	1147	risk
O	1148	1154	levels
O	1155	1156	1
O	1156	1157	,
O	1158	1159	2
O	1160	1163	and
O	1164	1165	3
O	1165	1166	,
O	1167	1179	respectively
O	1179	1180	.

B-outcome	1181	1189	Complete
I-outcome	1190	1197	control
I-outcome	1198	1200	of
I-outcome	1201	1206	acute
I-outcome	1207	1210	and
I-outcome	1211	1218	delayed
I-outcome	1219	1227	vomiting
O	1228	1231	was
O	1232	1242	comparable
O	1243	1246	and
O	1247	1250	was
O	1251	1259	achieved
O	1260	1262	in
O	1263	1267	over
O	1268	1270	85
O	1271	1272	%
O	1273	1275	of
O	1276	1284	patients
O	1285	1291	across
O	1292	1295	all
O	1296	1300	risk
O	1301	1307	levels
O	1308	1309	(
O	1309	1310	p
O	1311	1312	=
O	1313	1314	0
O	1314	1315	.
O	1315	1317	56
O	1318	1321	and
O	1322	1323	p
O	1324	1325	=
O	1326	1327	0
O	1327	1328	.
O	1328	1330	99
O	1330	1331	)
O	1331	1332	.

O	1333	1335	In
O	1336	1344	contrast
O	1344	1345	,
B-outcome	1346	1354	complete
I-outcome	1355	1362	control
I-outcome	1363	1365	of
I-outcome	1366	1371	acute
I-outcome	1372	1375	and
I-outcome	1376	1383	delayed
I-outcome	1384	1390	nausea
O	1391	1394	was
O	1395	1402	reduced
O	1403	1405	in
O	1406	1410	risk
O	1411	1417	levels
O	1418	1419	1
O	1420	1422	to
O	1423	1424	3
O	1425	1433	compared
O	1434	1436	to
O	1437	1442	level
O	1443	1444	0
O	1445	1446	(
O	1446	1451	acute
O	1452	1453	=
O	1454	1456	51
O	1456	1457	.
O	1457	1458	2
O	1458	1459	,
O	1460	1462	58
O	1462	1463	.
O	1463	1464	0
O	1464	1465	,
O	1466	1468	45
O	1468	1469	.
O	1469	1470	7
O	1471	1473	vs
O	1473	1474	.
O	1475	1477	70
O	1477	1478	.
O	1478	1479	0
O	1480	1481	%
O	1481	1482	;
O	1483	1484	p
O	1485	1486	=
O	1487	1488	0
O	1488	1489	.
O	1489	1492	013
O	1492	1493	)
O	1493	1494	-
O	1494	1495	(
O	1495	1502	delayed
O	1503	1504	=
O	1505	1507	32
O	1507	1508	.
O	1508	1509	8
O	1509	1510	,
O	1511	1513	45
O	1513	1514	.
O	1514	1515	7
O	1515	1516	,
O	1517	1519	34
O	1519	1520	.
O	1520	1521	6
O	1522	1524	vs
O	1524	1525	.
O	1526	1528	62
O	1528	1529	.
O	1529	1530	5
O	1531	1532	%
O	1532	1533	;
O	1534	1535	p
O	1536	1537	<
O	1538	1539	0
O	1539	1540	.
O	1540	1543	001
O	1543	1544	)
O	1544	1545	.

O	1546	1553	Despite
O	1554	1557	the
O	1558	1566	addition
O	1567	1569	of
O	1570	1580	aprepitant
O	1580	1581	,
O	1582	1590	extended
O	1590	1591	-
O	1591	1599	duration
O	1600	1613	dexamethasone
O	1614	1617	and
O	1618	1628	olanzapine
O	1628	1629	,
O	1630	1638	patients
O	1639	1641	at
O	1642	1646	high
O	1647	1651	risk
O	1652	1655	for
O	1656	1660	CINV
O	1661	1664	due
O	1665	1667	to
O	1668	1676	personal
O	1677	1681	risk
O	1682	1689	factors
O	1690	1696	failed
O	1697	1699	to
O	1700	1707	achieve
O	1708	1712	good
O	1713	1719	nausea
O	1720	1727	control
O	1727	1728	.
